Phase IIa, randomized, double-blind, placebo-controlled, parallel group and multicenter clinical trial to evaluate the safety, tolerability and therapeutic efficacy of daily oral treatment with NFX88 on neuropathic pain in patients with spinal cord injury.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: NEUROFIX SL
- Phase: II
- Execution start: 07/06/2019
- End of execution: 30/12/2019
- IP: MIGUEL DAVID MEMBRILLA TABLE